Quest Diagnostics Incorporated $DGX Stock: SGL Investment Advisors Inc. Cuts Holdings

SGL Investment Advisors Inc. decreased its holdings in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 21.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,416 shares of the medical research company’s stock after selling 5,874 shares during the period. Quest Diagnostics comprises approximately 1.9% of SGL Investment Advisors Inc.’s investment portfolio, making the stock its 18th biggest holding. SGL Investment Advisors Inc.’s holdings in Quest Diagnostics were worth $5,475,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Quest Diagnostics during the second quarter worth approximately $1,965,923,000. Bank of America Corp DE bought a new stake in shares of Quest Diagnostics during the 2nd quarter valued at $410,151,000. Legal & General Group Plc acquired a new stake in Quest Diagnostics during the second quarter worth about $151,986,000. Bank of New York Mellon Corp acquired a new stake in shares of Quest Diagnostics during the 2nd quarter worth approximately $133,388,000. Finally, Deutsche Bank AG acquired a new stake in shares of Quest Diagnostics during the 2nd quarter worth approximately $124,180,000. 88.06% of the stock is owned by institutional investors.

Insider Transactions at Quest Diagnostics

In other news, Director Gary Pfeiffer sold 1,203 shares of the stock in a transaction dated Monday, October 26th. The stock was sold at an average price of $243.00, for a total value of $292,329.00. Following the completion of the sale, the director owned 29,802 shares of the company’s stock, valued at approximately $7,241,886. This represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patrick Plewman sold 11,717 shares of the stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $257.34, for a total transaction of $3,015,252.78. Following the sale, the senior vice president directly owned 14,684 shares of the company’s stock, valued at $3,778,780.56. This represents a 44.38% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 67,702 shares of company stock worth $16,730,269. 0.88% of the stock is currently owned by insiders.

Quest Diagnostics Price Performance

Shares of NYSE:DGX opened at $259.46 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.58 and a current ratio of 1.70. Quest Diagnostics Incorporated has a 52 week low of $171.18 and a 52 week high of $262.00. The firm has a market cap of $28.55 billion, a PE ratio of 25.84, a price-to-earnings-growth ratio of 2.32 and a beta of 0.54. The firm’s fifty day moving average is $241.23 and its 200-day moving average is $215.58.

Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its quarterly earnings data on Thursday, October 22nd. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.87 by $0.13. The business had revenue of $3.10 billion during the quarter, compared to the consensus estimate of $3.05 billion. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. Quest Diagnostics’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.60 earnings per share. Sell-side analysts predict that Quest Diagnostics Incorporated will post 11.29 earnings per share for the current year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 27th. Shareholders of record on Tuesday, January 12th will be given a $0.86 dividend. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date is Tuesday, January 12th. Quest Diagnostics’s payout ratio is 34.26%.

Analyst Ratings Changes

Several brokerages have commented on DGX. Argus set a $260.00 price objective on shares of Quest Diagnostics in a research report on Wednesday, July 29th. Mizuho raised their target price on Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Barclays raised their target price on Quest Diagnostics from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Robert W. Baird set a $262.00 price target on Quest Diagnostics in a research note on Friday, October 23rd. Finally, Truist Financial boosted their price target on Quest Diagnostics from $250.00 to $260.00 and gave the stock a “hold” rating in a report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $248.70.

Check Out Our Latest Stock Analysis on DGX

Key Quest Diagnostics News

These are some of the DGX news items that stood out recently:

  • Positive Sentiment: Quest announced a quarterly dividend of $0.86 per share, equivalent to $3.44 annually and a stated yield of about 1.3%. The announcement coincided with DGX reaching a new one-year high. Quest Diagnostics hits a one-year high following dividend announcement
  • Neutral Sentiment: SVP Patrick Plewman sold 11,717 shares for about $3.02 million, reducing his holdings by 44.38%. The sale was made under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive signal about his view of the company. Quest Diagnostics insider share sale
  • Negative Sentiment: Zacks lowered its Q4 2026 EPS estimate to $2.66 from $2.70, partially offsetting the upward revisions for other periods.

Quest Diagnostics Company Profile

(Free Report)

Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.

Featured Articles

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.